Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW INDICATIONS

Tecentriq First Immunotherapy FDA Approved for Adjuvant Treatment of Early-Stage Non–Small-Cell Lung Cancer

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 15, 2021, the FDA accelerated the approval of a new indication for atezolizumab (Tecentriq; Genentech), for the adjuvant treatment, after resection and platinum-based chemotherapy, of patients with stage II-IIIA non–small-cell lung cancer (NSCLC) and PD-L1 expression ≥1%, as determined by an FDA-approved test.

Atezolizumab is the first immunotherapy to receive FDA approval for the adjuvant treatment of early-stage (stage II-IIIA) NSCLC. This approval was based on recent results from the phase 3 IMpower010 clinical trial.

Simultaneously, the FDA also approved the VENTANA PD-L1 Assay (Ventana Medical Systems) as a companion diagnostic test to identify appropriate patients with NSCLC for adjuvant treatment with atezolizumab.

“Too many patients with early-stage lung cancer experience disease recurrence following surgery. Now, the availability of immunotherapy following surgery and chemotherapy offers many patients new hope and a powerful new tool to reduce their risk of cancer relapse,” said Bonnie Addario, Co-Founder and Chair, GO2 Foundation for Lung Cancer. “With this approval, it is more important than ever to screen for lung cancer early and test for PD-L1 at diagnosis to help bring this advance to the people who can benefit.”

The major efficacy outcome was disease-free survival (DFS), as assessed by the investigator in the primary efficacy analysis population. The study included 476 patients with stage II-IIIA NSCLC and PD-L1 expression ≥1% who received atezolizumab or best supportive care.

The median DFS was not reached (95% confidence interval [CI], 36.1-not estimable [NE]) in the atezolizumab arm versus 35.3 months (95% CI, 29.0-NE) in patients in the best supportive care arm (hazard ratio, 0.66; 95% CI, 0.50-0.88; P = .004).

In a prespecified secondary subgroup analysis of patients with stage II-IIIA NSCLC and PD-L1 expression ≥50%, the hazard ratio for DFS was 0.43 (95% CI, 0.27- 0.68). And in an exploratory subgroup analysis of patients with stage II-IIIA NSCLC and PD-L1 expression of 1% to 49%, the hazard ratio for DFS was 0.87 (95% CI, 0.60-1.26).

The most common (≥10%) adverse reactions (including laboratory abnormalities) with atezolizumab in this study were increased aspartate aminotransferase, blood creatinine, and alanine aminotransferase; hyperkalemia, rash, cough, hypothyroidism, pyrexia, fatigue/asthenia, musculoskeletal pain, peripheral neuropathy, arthralgia, and pruritus.

Related Items
Cytalux, a Novel Imaging Agent, FDA Approved for Diagnosing Inoperable Ovarian Cancer Lesions
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination FDA Approved for Multiple Myeloma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda Now FDA Approved for Adjuvant Treatment of Renal-Cell Carcinoma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.